[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20083845L - 2,4-diaminopyrimidiner som celle-cyklus kinase inhibitorer - Google Patents

2,4-diaminopyrimidiner som celle-cyklus kinase inhibitorer

Info

Publication number
NO20083845L
NO20083845L NO20083845A NO20083845A NO20083845L NO 20083845 L NO20083845 L NO 20083845L NO 20083845 A NO20083845 A NO 20083845A NO 20083845 A NO20083845 A NO 20083845A NO 20083845 L NO20083845 L NO 20083845L
Authority
NO
Norway
Prior art keywords
diaminopyrimidines
cell cycle
kinase inhibitors
cycle kinase
excessive
Prior art date
Application number
NO20083845A
Other languages
English (en)
Inventor
Ulrike Tontsch-Grunt
Flavio Solca
Matthias Treu
Stephan Karl Zahn
Guido Boehmelt
Ulrich Reiser
Ulrich Guertler
Bojan Bister
Andreas Mantoulidis
Andreas Schoop
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37102115&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083845(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO20083845L publication Critical patent/NO20083845L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse omfatter forbindelser med den generelle formel (1) hvor R1, R2, R4, Rg, X, m, n og p er som definert i krav 1, som er egnet for behandling av sykdommer kjennetegnet ved for høy eller unormal celleproliferasjon, samt anvendelse av dem for fremstilling av et farmasøytisk preparat med de ovennevnte egenskaper.
NO20083845A 2006-05-15 2008-09-05 2,4-diaminopyrimidiner som celle-cyklus kinase inhibitorer NO20083845L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06113967 2006-05-15
PCT/EP2007/054723 WO2007132010A1 (de) 2006-05-15 2007-05-15 2, 4 -diamino pyrimidine als inhibitoren von zellzykluskinasen

Publications (1)

Publication Number Publication Date
NO20083845L true NO20083845L (no) 2008-12-11

Family

ID=37102115

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083845A NO20083845L (no) 2006-05-15 2008-09-05 2,4-diaminopyrimidiner som celle-cyklus kinase inhibitorer

Country Status (21)

Country Link
US (1) US8623887B2 (no)
EP (2) EP2357181A1 (no)
JP (1) JP5247681B2 (no)
KR (1) KR20090018955A (no)
CN (1) CN101443325A (no)
AR (1) AR060890A1 (no)
AT (1) ATE545641T1 (no)
AU (1) AU2007251553A1 (no)
BR (1) BRPI0712400A2 (no)
CA (1) CA2647238A1 (no)
EA (1) EA200802214A1 (no)
EC (1) ECSP088905A (no)
IL (1) IL195218A0 (no)
MX (1) MX2008014500A (no)
NO (1) NO20083845L (no)
NZ (1) NZ573506A (no)
PE (2) PE20120006A1 (no)
TW (1) TW200815392A (no)
UA (1) UA94944C2 (no)
WO (1) WO2007132010A1 (no)
ZA (1) ZA200807581B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010513406A (ja) * 2006-12-22 2010-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌治療のための細胞周期キナーゼ阻害剤としての２−［（フェニルアミノ）−ピリミジン−４−イルアミノ］−シクロペンタンカルボキサミド誘導体及び関連化合物
PE20090837A1 (es) 2007-07-02 2009-07-24 Boehringer Ingelheim Int Nuevos compuestos quimicos
EP2268621A1 (en) * 2008-03-20 2011-01-05 Boehringer Ingelheim International GmbH Regioselective preparation of substituted pyrimidines
UY31714A (es) * 2008-03-20 2009-11-10 Boehringer Ingelheim Int Preparación selectiva de pirimidinas sustituidas
CL2009000600A1 (es) * 2008-03-20 2010-05-07 Bayer Cropscience Ag Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas.
PE20110294A1 (es) 2008-09-29 2011-05-26 Boehringer Ingelheim Int Compuestos heterociclicos como inhibidores de enzimas de senal especifica
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) * 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US8466155B2 (en) * 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
JP5871897B2 (ja) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジルトリアゾール
US20120107304A1 (en) * 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
EP3075730B1 (en) 2010-06-04 2018-10-24 Genentech, Inc. Aminopyrimidine derivatives as lrrk2 modulators
WO2012059932A1 (en) * 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
RS56583B1 (sr) 2010-11-10 2018-02-28 Genentech Inc Derivati pirazol aminopirimidina kao lrrk2 modulatori
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
CN105793251B (zh) * 2013-12-05 2018-10-12 豪夫迈·罗氏有限公司 具有亲电子官能性的杂芳基吡啶酮和氮杂-吡啶酮化合物
WO2015095679A1 (en) * 2013-12-20 2015-06-25 Signal Pharmaceuticals, Llc Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012485A1 (en) 1998-08-29 2000-03-09 Astrazeneca Ab Pyrimidine compounds
JP3635238B2 (ja) * 1998-11-10 2005-04-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖの複製を阻害するピリミジン類
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
IL159120A0 (en) * 2001-05-29 2004-05-12 Schering Ag Cdk inhibiting pyrimidines, production thereof and their use as medicaments
ATE451104T1 (de) 2002-07-29 2009-12-15 Rigel Pharmaceuticals Inc Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen
US7514446B2 (en) 2003-02-20 2009-04-07 Smithkline Beecham Corporation Pyrimidine compounds
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
WO2005013996A2 (en) * 2003-08-07 2005-02-17 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
EP1763514A2 (en) * 2004-05-18 2007-03-21 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
EP1598343A1 (de) * 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
US7521457B2 (en) * 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors

Also Published As

Publication number Publication date
WO2007132010A1 (de) 2007-11-22
ZA200807581B (en) 2010-05-26
PE20120006A1 (es) 2012-02-02
MX2008014500A (es) 2008-11-27
KR20090018955A (ko) 2009-02-24
AR060890A1 (es) 2008-07-23
NZ573506A (en) 2011-12-22
CA2647238A1 (en) 2007-11-22
ECSP088905A (es) 2008-12-30
PE20080068A1 (es) 2008-03-17
BRPI0712400A2 (pt) 2012-10-16
IL195218A0 (en) 2009-09-22
TW200815392A (en) 2008-04-01
US20090163467A1 (en) 2009-06-25
ATE545641T1 (de) 2012-03-15
EP2027107A1 (de) 2009-02-25
EP2027107B1 (de) 2012-02-15
JP5247681B2 (ja) 2013-07-24
UA94944C2 (ru) 2011-06-25
EA200802214A1 (ru) 2009-06-30
AU2007251553A1 (en) 2007-11-22
EP2357181A1 (de) 2011-08-17
CN101443325A (zh) 2009-05-27
US8623887B2 (en) 2014-01-07
JP2009537485A (ja) 2009-10-29

Similar Documents

Publication Publication Date Title
NO20083845L (no) 2,4-diaminopyrimidiner som celle-cyklus kinase inhibitorer
NO20076059L (no) 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer
NO20081729L (no) Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
NO20085176L (no) Fenyl substituerte heteroaryl-derivater og andvendelse som anti-tumor agenter
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
NO20092412L (no) Hydantoinderivater anvendes som MMP-inhibitorer
NO20070655L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
CA2620129C (en) Diaminopyrimidines as p2x3 and p2x2/3 modulators
NO20081217L (no) Nye benzotiazolonderivater
NO20084850L (no) MGLUR5 modulatorer I
NO20074275L (no) 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister
NO20081554L (no) Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
MX2007015863A (es) Inhibidores de esfingosina cinasa.
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
NO20064588L (no) Delta d-krystallinsk form av ivabradin-hydroklorid, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende den
NO20081454L (no) Met-kinaseinhibitorer
TW200738659A (en) Novel compounds
TW200740773A (en) Diaminopyrimidines as P2X3 and P2X2/3 modulators
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
TW200740799A (en) Alpha2C adrenoreceptor agonists
NO20084712L (no) Nye farmasoytiske forbindelser
TW200745084A (en) Novel compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application